4//SEC Filing
OrbiMed Capital GP III LLC 4
Accession 0000947871-18-000654
CIK 0001597313other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 7:36 PM ET
Size
51.1 KB
Accession
0000947871-18-000654
Insider Transaction Report
Form 4
ViewRay, Inc.VRAY
OrbiMed Capital GP III LLC
10% Owner
Transactions
- Sale
Common Stock
2018-08-08$10.00/sh−478,107$4,781,070→ 8,749,057 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+431$2,155→ 82,897 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.86/sh−26,139$257,731→ 8,614,189 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-10$9.96/sh−6,460$64,342→ 75,573 total(indirect: See Footnotes) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−431→ 0 total(indirect: See Footnotes)Exercise: $8.02Exp: 2018-09-25→ Common Stock (431 underlying) - Exercise/Conversion
Restricted Stock Unit
2018-08-07−249→ 0 total(indirect: See Footnotes)→ Common Stock (249 underlying) - Exercise/Conversion
Common Stock
2018-08-07+26,139→ 9,227,164 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.91/sh−64,575$639,938→ 8,640,328 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.91/sh−615$6,095→ 82,282 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.86/sh−249$2,455→ 82,033 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-10$9.96/sh−678,333$6,756,197→ 7,935,856 total(indirect: See Footnotes) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−184→ 0 total(indirect: See Footnotes)Exercise: $5.00Exp: 2018-09-25→ Common Stock (184 underlying) - Exercise/Conversion
Common Stock
2018-08-07+249→ 87,871 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.95/sh−108,729$1,081,854→ 8,640,328 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.95/sh−1,036$10,308→ 82,282 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+19,372$96,860→ 8,659,700 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+45,203$226,015→ 8,704,903 total(indirect: See Footnotes) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−45,203→ 0 total(indirect: See Footnotes)Exercise: $8.02Exp: 2018-09-25→ Common Stock (45,203 underlying) - Sale
Common Stock
2018-08-08$10.00/sh−4,553$45,530→ 83,318 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+184$920→ 82,466 total(indirect: See Footnotes) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−19,372→ 0 total(indirect: See Footnotes)Exercise: $5.00Exp: 2018-09-25→ Common Stock (19,372 underlying) - Exercise/Conversion
Restricted Stock Unit
2018-08-07−26,139→ 0 total(indirect: See Footnotes)→ Common Stock (26,139 underlying)
ORBIMED ADVISORS LLC
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2018-08-07+249→ 87,871 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-08$10.00/sh−4,553$45,530→ 83,318 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.95/sh−108,729$1,081,854→ 8,640,328 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.95/sh−1,036$10,308→ 82,282 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+19,372$96,860→ 8,659,700 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.91/sh−64,575$639,938→ 8,640,328 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-07+26,139→ 9,227,164 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-10$9.96/sh−678,333$6,756,197→ 7,935,856 total(indirect: See Footnotes) - Exercise/Conversion
Restricted Stock Unit
2018-08-07−249→ 0 total(indirect: See Footnotes)→ Common Stock (249 underlying) - Sale
Common Stock
2018-08-08$10.00/sh−478,107$4,781,070→ 8,749,057 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+184$920→ 82,466 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+45,203$226,015→ 8,704,903 total(indirect: See Footnotes) - Exercise/Conversion
Common Stock
2018-08-09$5.00/sh+431$2,155→ 82,897 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.91/sh−615$6,095→ 82,282 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.86/sh−249$2,455→ 82,033 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-10$9.96/sh−6,460$64,342→ 75,573 total(indirect: See Footnotes) - Sale
Common Stock
2018-08-09$9.86/sh−26,139$257,731→ 8,614,189 total(indirect: See Footnotes) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−19,372→ 0 total(indirect: See Footnotes)Exercise: $5.00Exp: 2018-09-25→ Common Stock (19,372 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−184→ 0 total(indirect: See Footnotes)Exercise: $5.00Exp: 2018-09-25→ Common Stock (184 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−45,203→ 0 total(indirect: See Footnotes)Exercise: $8.02Exp: 2018-09-25→ Common Stock (45,203 underlying) - Exercise/Conversion
Restricted Stock Unit
2018-08-07−26,139→ 0 total(indirect: See Footnotes)→ Common Stock (26,139 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-08-09−431→ 0 total(indirect: See Footnotes)Exercise: $8.02Exp: 2018-09-25→ Common Stock (431 underlying)
Footnotes (9)
- [F1]The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $9.98 to $10.07 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $9.90 to $10.03 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
- [F3]The stock options were included in an award to David Bonita, an employee of the Reporting Persons, made on July 23, 2015 for services as a director of the Issuer. The award included stock options relating to a total of 19,556 shares of the Issuer's Common Stock and was vested and exercisable on July 23, 2016. Mr. Bonita is no longer a director of the Issuer.
- [F4]The stock options were included in an award to David Bonita, an employee of the Reporting Persons, made on November 15, 2017 for services as a director of the Issuer. The award included stock options relating to a total of 45,633 shares of the Issuer's Common Stock and was vested and exercisable on June 19, 2018. Mr. Bonita is no longer a director of the Issuer.
- [F5]The restricted stock units were included in an award to David Bonita, an employee of the Reporting Persons, made on November 15, 2017 for services as a director of the Issuer. Each restricted stock unit represented a contingent right to receive one Share following Mr. Bonita's termination of service from the Issuer's board of directors.
- [F6]The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $9.88 to $10.03 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
- [F7]These securities are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III.
- [F8]These securities are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. By virtue of such relationships, Advisors may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by Associates III.
- [F9]This report on Form 4 is jointly filed by GP III and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
ViewRay, Inc.
CIK 0001597313
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001432241
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 7:36 PM ET
- Size
- 51.1 KB